Table of Contents
The Innovative Therapies Centers of Excellence Act of 2025, a bipartisan Senate bill, would allocate $30 million per year to fund at least five VA medical facilities offering research and treatment using psilocybin, MDMA, ibogaine, and DMT for veterans. The bill has not yet passed into law.
- Bipartisan momentum: The bill is co-sponsored by Sen. Ruben Gallego (D-AZ) and Sen. Dave McCormick (R-PA), suggesting cross-party interest in expanding veteran access to psychedelic-assisted therapies.
- Broad scope of compounds and conditions: The legislation names psilocybin, MDMA, ibogaine, and DMT as covered substances, and targets conditions ranging from PTSD and depression to chronic pain and Parkinson’s disease.
- Research-first structure: Funding would support research and education through VA centers affiliated with accredited medical, psychiatry, and social work schools, not open clinical access to the general veteran population.
- Early-stage VA context: The VA’s own press secretary noted in November 2025 that psychedelic research at the agency is at an early stage, with trial results expected years out, meaning this bill addresses a field still building its evidence base.
What the Research Examined
This recap covers proposed federal legislation, not a clinical study. The Military.com report published March 9, 2026, describes the Innovative Therapies Centers of Excellence Act of 2025, introduced by Sen. Ruben Gallego (D-AZ) and co-sponsored by Sen. Dave McCormick (R-PA). The bill would direct the VA to designate no fewer than five medical facilities capable of conducting research and providing education on psychedelic-assisted therapies, with geographic distribution overseen by VA leadership. Each center would be required to affiliate with accredited schools of medicine, psychiatry, and social work, and would be evaluated by a peer review panel composed of innovative therapy experts.
The legislation would appropriate $30 million annually to fund these centers’ research and education activities. Covered substances include psilocybin, MDMA, ibogaine, and DMT, along with any additional compounds the VA under secretary may designate. Covered conditions span PTSD, depression, anxiety, bipolar disorder, chronic pain, substance use disorder, and Parkinson’s disease. The bill also calls for a national medical data repository to track health outcomes for veterans receiving innovative therapies, and mandates a formal report to both the Senate and House Veterans’ Affairs committees within two years of the peer review panel’s establishment.
This legislative push follows the VA’s November 2025 announcement, reported separately by Military.com, that it was expanding psychedelic-assisted therapy trials under strict Schedule I regulatory procedures. The VA described that work as early-stage, with results anticipated years away. Understanding where this bill fits within the broader arc of federal psychedelic policy for veterans helps clarify that this is one legislative effort in a still-forming landscape, not a finalized program.
What the Findings Show
- Annual funding proposed.$30 million per fiscal year would be appropriated to support research and education activities at the designated VA centers, if the bill passes.
- Minimum number of centers.No fewer than five VA medical facilities would be designated, with geographic distribution required across the country.
- Compounds named in the bill.Four substances are explicitly listed: psilocybin, MDMA, ibogaine, and DMT. The VA under secretary would have authority to add others.
- Covered conditions.Eight conditions are named, including PTSD, depression, anxiety, chronic pain, bipolar disorder, substance use disorder, and Parkinson’s disease, with room for additional designations.
The VA’s own public statements, cited in the Military.com article, frame the agency’s current psychedelic research as early-stage work proceeding under Schedule I controls. That context matters here: this bill, if passed, would build infrastructure and fund research rather than immediately open psychedelic-assisted therapy to all eligible veterans. The gap between legislative intent and clinical availability is real, and the VA has said results from current trials will not be ready for years.
What would the Innovative Therapies Centers of Excellence Act do for veterans seeking psilocybin therapy?
If passed, the bill would fund at least five VA research centers studying psilocybin and other psychedelic compounds for conditions like PTSD and depression, allocating $30 million annually. It would not immediately provide open access to treatment; its focus is research, education, and building clinical infrastructure within the VA system.
What This Is, and What It Is Not
This is This is a legislative news report describing a proposed Senate bill that has not yet become law, not a peer-reviewed clinical study or trial result.
This is not This is not evidence that psilocybin or any other named compound is an approved or proven treatment for PTSD or any other condition. Nothing here constitutes medical advice, and veterans interested in mental health support should consult qualified healthcare providers through the VA or other licensed channels.
Our Take
For those of us who hold psilocybin as a sacrament, watching federal legislation move toward acknowledging its potential is a complicated kind of moment. The language in this bill is clinical and institutional by design, as it should be in a legislative context. But beneath the appropriations figures and committee structures is something older: the recognition that the tools our tradition has honored for generations may have something real to offer people who are suffering. Veterans carry weight that most of us cannot fully imagine. If rigorous, well-funded research within the VA system can move the understanding of these compounds forward in an honest and careful way, that seems worth supporting, even as we hold the fuller meaning of this medicine close.
Whether you found this piece through a concern for a veteran you love, a curiosity about where the law is heading, or your own quiet relationship with these medicines, you are welcome here. The Church of Psychedelics holds space for all of it: the political, the personal, the sacred, and the still-unproven. If you want to stay close to how research and policy develop in real time, our newsletter is a good place to do that. We report carefully, hedge honestly, and never mistake hope for evidence. Walk alongside us.
Frequently Asked Questions
Has the Innovative Therapies Centers of Excellence Act passed into law?
As of the March 2026 reporting by Military.com, the bill had been introduced in the Senate but had not yet become law. It remains proposed legislation requiring further congressional action.
Which psychedelic substances does the VA bill cover?
The bill explicitly names psilocybin, MDMA, ibogaine, and DMT. It also allows the VA under secretary for health to designate additional substances as covered innovative therapies.
Would veterans be able to receive psilocybin therapy at the VA if this bill passes?
The bill funds research and education centers, not open clinical treatment. The VA has stated its psychedelic research is early-stage and results from ongoing trials are years away. Passage of the bill would expand infrastructure, not guarantee immediate patient access.
Is the VA already researching psychedelics for PTSD?
Yes. The VA confirmed in November 2025 that it was expanding psychedelic-assisted therapy trials for PTSD, treatment-resistant depression, and anxiety, conducted under strict Schedule I regulatory procedures. The VA described this as early-stage work.
Who sponsored the Innovative Therapies Centers of Excellence Act?
Sen. Ruben Gallego, a Democrat from Arizona and Marine Corps combat veteran, sponsored the bill. Sen. Dave McCormick, a Republican from Pennsylvania, is listed as a co-sponsor, making it bipartisan legislation.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
